MBX Biosciences, Inc.
MBX Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity on October 30, 2026. There are 4 upcoming events on record.
Cash runway is approximately 62.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 30, 2026 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity | Trial Milestone | Phase 1 |
| December 18, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 15, 2028 | A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism | Trial Milestone | Phase 3 |
| May 15, 2028 | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | Trial Milestone | Phase 2 |
Track MBX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MBX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.